for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Emergent Biosolutions Inc

EBS.N

Latest Trade

96.11USD

Change

-1.54(-1.58%)

Volume

255,037

Today's Range

95.91

 - 

100.44

52 Week Range

46.37

 - 

137.15

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Emergent's COVID-19 HIG Product Candidate To Be Included In NIH-Sponsored Trial To Treat COVID-19

Oct 8 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS’ COVID-19 HUMAN IMMUNE GLOBULIN PRODUCT CANDIDATE TO BE INCLUDED IN NIH-SPONSORED PHASE 3 CLINICAL TRIAL OF HYPERIMMUNE INTRAVENOUS IMMUNOGLOBULIN TO TREAT COVID-19.EMERGENT BIOSOLUTIONS - PLANNING MORE TRIALS TO EVALUATE COVID-HIG FOR POTENTIAL USE IN OTHER PATIENT POPULATIONS/INDIVIDUALS AT HIGH EXPOSURE RISK.

Emergent Biosolutions Announces FDA Approval Of Narcan Nasal Spray Shelf Life Extension To 36 Months

Aug 17 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS ANNOUNCES FDA APPROVAL OF NARCAN® (NALOXONE HCL) NASAL SPRAY SHELF LIFE EXTENSION TO 36 MONTHS.

Emergent Biosolutions Plans Offering Of $400 Mln Of Senior Unsecured Notes

Aug 4 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS ANNOUNCES PROPOSED OFFERING OF $400 MILLION OF SENIOR UNSECURED NOTES.EMERGENT BIOSOLUTIONS INC - INTENDS TO OFFER $400 MILLION AMOUNT OF SENIOR UNSECURED NOTES WITH AN EXPECTED MATURITY DATE OF AUGUST 2028.EMERGENT BIOSOLUTIONS INC - INTENDS TO USE NET PROCEEDS OF OFFERING TO REPAY $353 MILLION OUTSTANDING UNDER ITS $600 MILLION REVOLVING CREDIT FACILITY.

Emergent Biosolutions Reports Q2 Adj. EPS Of $1.98

July 30 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2020 AND REVISES UPWARD FULL YEAR 2020 GUIDANCE.Q2 ADJUSTED EARNINGS PER SHARE $1.98.Q2 EARNINGS PER SHARE $1.73.Q2 REVENUE $394.7 MILLION.Q2 REVENUE ESTIMATE $294.7 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $0.68 -- REFINITIV IBES DATA.SEES Q3 2020 REVENUE $420 MILLION TO $450 MILLION.SEES 2020 TOTAL REVENUES $1,500 - $1,600 MILLION.SEES 2020 ADJUSTED EBITDA $535 - $600 MILLION.FY2020 REVENUE VIEW $1.39 BILLION -- REFINITIV IBES DATA.Q3 REVENUE VIEW $420.2 MILLION -- REFINITIV IBES DATA.

Emergent Biosolutions Signs Agreement With Astrazeneca To Expand Manufacturing For COVID-19 Vaccine Candidate

July 27 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS SIGNS AGREEMENT WITH ASTRAZENECA TO EXPAND MANUFACTURING FOR COVID-19 VACCINE CANDIDATE.EMERGENT BIOSOLUTIONS INC - AGREEMENT IS VALUED AT APPROXIMATELY $174 MILLION THROUGH 2021 AND BRINGS TOTAL ASTRAZENECA COMMITMENT TO $261 MILLION.EMERGENT BIOSOLUTIONS - TO PROVIDE CONTRACT DEVELOPMENT AND MANUFACTURING SERVICES BEGINNING IN 2020 TO PRODUCE DRUG SUBSTANCE AT LARGE SCALE.EMERGENT BIOSOLUTIONS INC - AGREEMENT IS VALUED AT ABOUT $174 MILLION THROUGH 2021 AND BRINGS TOTAL ASTRAZENECA COMMITMENT TO $261 MILLION.

Mount Sinai Health System, Emergent Biosolutions, And Immunotek Bio Centers Collaborate To Develop Emergent's Covid-19 Hyperimmune Globulin Product Candidate With U.S. DoD

July 8 (Reuters) - Emergent BioSolutions Inc <EBS.N>::MOUNT SINAI HEALTH SYSTEM, EMERGENT BIOSOLUTIONS, AND IMMUNOTEK BIO CENTERS FORM COLLABORATION TO DEVELOP EMERGENT'S COVID-19 HYPERIMMUNE GLOBULIN (COVID-HIG) PRODUCT CANDIDATE WITH U.S. DEPARTMENT OF DEFENSE FUNDING.EMERGENT BIOSOLUTIONS - IMMUNOTEK TO EXTEND OPERATING LICENSE, PROVIDE TRAINING TO MOUNT SINAI TO ESTABLISH ONSITE PLASMA COLLECTION.EMERGENT BIOSOLUTIONS INC - COLLABORATION HAS FUNDING OF $34.6 MILLION FROM U.S. DEPARTMENT OF DEFENSE.EMERGENT BIOSOLUTIONS - WILL EVALUATE COVID-HIG IN A POST-EXPOSURE PROPHYLAXIS STUDY IN INDIVIDUALS AT HIGH RISK OF EXPOSURE TO COVID-19.EMERGENT BIOSOLUTIONS - WILL SUPPORT IMMUNOTEK, MOUNT SINAI IN OTHER REGULATORY, COMPLIANCE EFFORTS RELATED TO PLASMA COLLECTION & SUPPLY.

Emergent Biosolutions Says Will Begin Providing Large-Scale Drug Substance Manufacturing For Johnson & Johnson's Adenovirus-Based Covid-19 Vaccine In 2021

July 6 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS SIGNS FIVE-YEAR AGREEMENT FOR LARGE-SCALE DRUG SUBSTANCE MANUFACTURING FOR JOHNSON & JOHNSON’S LEAD COVID-19 VACCINE CANDIDATE.EMERGENT BIOSOLUTIONS- WILL BEGIN PROVIDING LARGE-SCALE DRUG SUBSTANCE MANUFACTURING FOR JOHNSON & JOHNSON'S ADENOVIRUS-BASED COVID-19 VACCINE IN 2021.EMERGENT BIOSOLUTIONS INC - WILL PROVIDE AN UPDATE TO ITS 2020 FINANCIAL OUTLOOK INCORPORATING EXPECTATIONS RELATED TO AGREEMENT.EMERGENT - WILL PROVIDE SERVICES PRODUCE DRUG SUBSTANCE AT LARGE SCALE FOR COMMERCIAL MANUFACTURING WITH FIRST 2 YEARS VALUED AT ABOUT $480 MILLION.EMERGENT BIOSOLUTIONS -FOR REMAINING 3 YEARS BEGINNING IN 2023, CO WILL PROVIDE FLEXIBLE CAPACITY DEPLOYMENT MODEL TO SUPPORT ANNUAL DOSE REQUIREMENTS.

Emergent Biosolutions To Become U.S. Manufacturing Partner For Astrazeneca's Covid-19 Vaccine Candidate

June 11 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS SIGNS AGREEMENT TO BE U.S. MANUFACTURING PARTNER FOR ASTRAZENECA’S COVID-19 VACCINE CANDIDATE.EMERGENT BIOSOLUTIONS - AGREEMENT VALUED AT APPROXIMATELY $87 MILLION.EMERGENT BIOSOLUTIONS - TO PROVIDE DEVELOPMENT, MANUFACTURING SERVICES & CAPACITY TO INNOVATORS OF LEADING COVID-19 VACCINE CANDIDATES SELECTED BY U.S. GOVERNMENT.EMERGENT BIOSOLUTIONS INC - UNDER AGREEMENT, CO WILL RESERVE CERTAIN LARGE-SCALE MANUFACTURING CAPACITY THROUGH 2020.

HHS - Emergent To Commit Manufacturing Capacity For Production Of Covid-19 Vaccine Candidates

June 1 (Reuters) - Emergent BioSolutions Inc <EBS.N>::HHS ADDS $628 MILLION TO CONTRACT WITH EMERGENT BIOSOLUTIONS TO SECURE CDMO MANUFACTURING CAPACITY FOR OPERATION WARP SPEED.HHS - ANNOUNCED TASK ORDER WITH EMERGENT BIOSOLUTIONS TO ADVANCE MANUFACTURING CAPABILITIES, CAPACITY FOR POTENTIAL COVID-19 VACCINE, THERAPEUTICS.HHS - EMERGENT TO COMMIT CDMO DRUG SUBSTANCE & DRUG PRODUCT MANUFACTURING CAPACITY OF ABOUT $542.75 MILLION FOR PRODUCTION OF COVID-19 VACCINE CANDIDATESSource text for Eikon: [ID:].

Emergent Biosolutions Through Unit Received Contract Modification From Office Of Assistant Secretary For Preparedness And Response

May 28 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS - THROUGH UNIT RECEIVED CONTRACT MODIFICATION FROM OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.EMERGENT BIOSOLUTIONS - CONTRACT MODIFICATION FROM ASPR EXERCISING FIRST OF NINE ANNUAL CONTRACT OPTIONS FOR CO TO SUPPLY ACAM2000 INTO U.S. SNS.EMERGENT BIOSOLUTIONS - FIRST OPTION EXERCISE IS VALUED AT ABOUT $176.2 MILLION.EMERGENT BIOSOLUTIONS - PERIOD OF PERFORMANCE UNDER FIRST OPTION EXERCISE REQUIRES EMERGENT TO DELIVER DOSES OF ACAM2000 INTO SNS BY DEC 31, 2020.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up